vs
AMERICAN WOODMARK CORP（AMWD）とANI PHARMACEUTICALS INC（ANIP）の財務データ比較。上の社名をクリックして会社を切り替えられます
AMERICAN WOODMARK CORPの直近四半期売上が大きい（$394.6M vs $247.1M、ANI PHARMACEUTICALS INCの約1.6倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 1.5%、差は9.6%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -12.8%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $638.0K）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -3.3%）
アメリカン・ウッドマーク社はキッチン・バスルーム用キャビネットの製造メーカーで、本社はバージニア州ウィンチェスターに置かれています。同社は全米各地に複数の生産拠点とサービスセンターを展開しており、生産拠点はアリゾナ、ジョージアなど8州に分布し、サービスセンターは全米各地に設置されています。
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
AMWD vs ANIP — 直接比較
損益計算書 — Q2 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $394.6M | $247.1M |
| 純利益 | $6.1M | $27.5M |
| 粗利率 | 15.2% | — |
| 営業利益率 | 3.1% | 14.1% |
| 純利益率 | 1.5% | 11.1% |
| 売上前年比 | -12.8% | 29.6% |
| 純利益前年比 | -78.0% | 367.5% |
| EPS（希薄化後） | $0.42 | $1.14 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $394.6M | $247.1M | ||
| Q3 25 | $403.0M | $227.8M | ||
| Q2 25 | $400.4M | $211.4M | ||
| Q1 25 | $397.6M | $197.1M | ||
| Q4 24 | $452.5M | $190.6M | ||
| Q3 24 | $459.1M | $148.3M | ||
| Q2 24 | $453.3M | $138.0M | ||
| Q1 24 | $422.1M | $137.4M |
| Q4 25 | $6.1M | $27.5M | ||
| Q3 25 | $14.6M | $26.6M | ||
| Q2 25 | $25.6M | $8.5M | ||
| Q1 25 | $16.6M | $15.7M | ||
| Q4 24 | $27.7M | $-10.3M | ||
| Q3 24 | $29.6M | $-24.2M | ||
| Q2 24 | $26.8M | $-2.3M | ||
| Q1 24 | $21.2M | $18.2M |
| Q4 25 | 15.2% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 17.0% | — | ||
| Q1 25 | 15.0% | — | ||
| Q4 24 | 18.9% | — | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 18.6% | — | ||
| Q1 24 | 19.2% | — |
| Q4 25 | 3.1% | 14.1% | ||
| Q3 25 | 5.0% | 15.9% | ||
| Q2 25 | 7.4% | 6.6% | ||
| Q1 25 | 5.3% | 13.3% | ||
| Q4 24 | 9.4% | -2.3% | ||
| Q3 24 | 10.2% | -13.8% | ||
| Q2 24 | 8.4% | 3.7% | ||
| Q1 24 | 6.6% | 14.8% |
| Q4 25 | 1.5% | 11.1% | ||
| Q3 25 | 3.6% | 11.7% | ||
| Q2 25 | 6.4% | 4.0% | ||
| Q1 25 | 4.2% | 8.0% | ||
| Q4 24 | 6.1% | -5.4% | ||
| Q3 24 | 6.5% | -16.3% | ||
| Q2 24 | 5.9% | -1.7% | ||
| Q1 24 | 5.0% | 13.2% |
| Q4 25 | $0.42 | $1.14 | ||
| Q3 25 | $1.00 | $1.13 | ||
| Q2 25 | $1.73 | $0.36 | ||
| Q1 25 | $1.09 | $0.69 | ||
| Q4 24 | $1.79 | $-0.45 | ||
| Q3 24 | $1.89 | $-1.27 | ||
| Q2 24 | $1.70 | $-0.14 | ||
| Q1 24 | $1.32 | $0.82 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $52.1M | $285.6M |
| 総負債低いほど良い | $363.3M | — |
| 株主資本純資産 | $928.2M | $540.7M |
| 総資産 | $1.6B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.39× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $52.1M | $285.6M | ||
| Q3 25 | $54.9M | $262.6M | ||
| Q2 25 | $48.2M | $217.8M | ||
| Q1 25 | $43.5M | $149.8M | ||
| Q4 24 | $56.7M | $144.9M | ||
| Q3 24 | $89.3M | $145.0M | ||
| Q2 24 | $87.4M | $240.1M | ||
| Q1 24 | $97.8M | $228.6M |
| Q4 25 | $363.3M | — | ||
| Q3 25 | $364.8M | — | ||
| Q2 25 | $365.8M | — | ||
| Q1 25 | $367.3M | — | ||
| Q4 24 | $368.0M | — | ||
| Q3 24 | $372.2M | — | ||
| Q2 24 | $371.8M | — | ||
| Q1 24 | $371.3M | — |
| Q4 25 | $928.2M | $540.7M | ||
| Q3 25 | $920.3M | $505.8M | ||
| Q2 25 | $916.0M | $436.8M | ||
| Q1 25 | $919.6M | $418.6M | ||
| Q4 24 | $915.1M | $403.7M | ||
| Q3 24 | $913.8M | $405.9M | ||
| Q2 24 | $910.4M | $455.8M | ||
| Q1 24 | $896.9M | $452.0M |
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.6B | $1.4B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.6B | $1.3B | ||
| Q2 24 | $1.6B | $920.8M | ||
| Q1 24 | $1.6B | $914.5M |
| Q4 25 | 0.39× | — | ||
| Q3 25 | 0.40× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.41× | — | ||
| Q2 24 | 0.41× | — | ||
| Q1 24 | 0.41× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $11.2M | $30.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $638.0K | $29.1M |
| FCFマージンFCF / 売上 | 0.2% | 11.8% |
| 設備投資強度設備投資 / 売上 | 2.7% | 0.5% |
| キャッシュ転換率営業CF / 純利益 | 1.83× | 1.10× |
| 直近12ヶ月FCF直近4四半期 | $64.0M | $171.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $11.2M | $30.4M | ||
| Q3 25 | $33.1M | $44.1M | ||
| Q2 25 | $44.8M | $75.8M | ||
| Q1 25 | $11.0M | $35.0M | ||
| Q4 24 | $11.9M | $15.9M | ||
| Q3 24 | $40.8M | $12.5M | ||
| Q2 24 | $43.3M | $17.4M | ||
| Q1 24 | $43.7M | $18.3M |
| Q4 25 | $638.0K | $29.1M | ||
| Q3 25 | $25.3M | $38.0M | ||
| Q2 25 | $35.8M | $71.8M | ||
| Q1 25 | $2.3M | $32.5M | ||
| Q4 24 | $1.1M | $13.5M | ||
| Q3 24 | $29.5M | $7.7M | ||
| Q2 24 | $7.2M | $13.0M | ||
| Q1 24 | $22.1M | $13.7M |
| Q4 25 | 0.2% | 11.8% | ||
| Q3 25 | 6.3% | 16.7% | ||
| Q2 25 | 8.9% | 34.0% | ||
| Q1 25 | 0.6% | 16.5% | ||
| Q4 24 | 0.2% | 7.1% | ||
| Q3 24 | 6.4% | 5.2% | ||
| Q2 24 | 1.6% | 9.4% | ||
| Q1 24 | 5.2% | 10.0% |
| Q4 25 | 2.7% | 0.5% | ||
| Q3 25 | 1.9% | 2.7% | ||
| Q2 25 | 2.2% | 1.9% | ||
| Q1 25 | 2.2% | 1.3% | ||
| Q4 24 | 2.4% | 1.3% | ||
| Q3 24 | 2.5% | 3.2% | ||
| Q2 24 | 8.0% | 3.2% | ||
| Q1 24 | 5.1% | 3.3% |
| Q4 25 | 1.83× | 1.10× | ||
| Q3 25 | 2.27× | 1.66× | ||
| Q2 25 | 1.75× | 8.87× | ||
| Q1 25 | 0.66× | 2.23× | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 1.62× | — | ||
| Q1 24 | 2.06× | 1.00× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMWD
| Home Center Retailers | $166.7M | 42% |
| Builders | $164.7M | 42% |
| Independent Dealersand Distributors | $63.2M | 16% |
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
